• Users Online: 996
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2017  |  Volume : 3  |  Issue : 2  |  Page : 27-30

Outcomes of Multiple Myeloma in The Era of Novel Agents: A Retrospective Study from Tertiary Cancer Centre


1 Department of Medical Oncology, Indira Gandhi Institute of Medical Sciences, Patna, India
2 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
3 Department of Cytogenetics, Tata Memorial Hospital, Mumbai, India

Correspondence Address:
Pandey Avinash
Assistant Professor, Medical oncology, IGIMS, Patna
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: Multiple myeloma is a plasma cell neoplasm characterised by skeletal destruction, renal failure, anaemia and hypercalcemia. Use of novel agents have led to significant increase in response rates and hence, limited the benefits of transplant. Aims and Objectives: To evaluate outcomes and toxicities with use of novel agents. To evaluate Progression Free Survival, Overall Survival and factors affecting outcome. Material and Methods: Case records of all patients diagnosed as Multiple Myeloma registered between 1st January 2012 to 31st December 2013 have been retrospectively analysed. Demographic data was collected along with response rates, date of progression and death. Toxicity with use of novel agents was recorded. Progression free survival and Overall Survival was analyzed with the Kaplan-Meier method. Log-rank tests was utilized to assess the differences in outcomes between various subgroups. Results: Total 101 patients were analysed out of which 90 were multiple myeloma and 11 had light chain disease. Median age of presentation was 56 years with male:female ratio of 3:1. Median time to best response was 4 months. Median follow up was 36 months with median time to second treatment 18 months. Response rates with VGPR (very good partial response) and PR (partial response) was seen in 60% of patients. Median progression free survival was 18 months while median overall survival was not reached. Out of 15 deaths, 7 patients had progressive disease, 6 had stable disease and 2 had partial response at the time of last assessment. Conclusion: Use of novel agents in the management of multiple myeloma improved response rates and outcomes. Majority of patients including those with higher stage or high risk cytogenetic enjoyed better response rates and longer duration of remission. Despite such advances, prognosis of stage III patients needs further improvement with newer strategies for better outcome.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed434    
    Printed14    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal